Limits...
HMGB-1 as a novel predictor of disease severity and prognosis in patients with hemorrhagic fever with renal syndrome.

Du H, Li J, Yu H, Lian J, Zhang Y, Zhang Y, Bai X, Wang P - Mediators Inflamm. (2015)

Bottom Line: HMGB-1 was positively correlated with WBC and BUN and negatively correlated with PLT, ALB, and UA (P < 0.001).HMGB-1 showed statistical significance for predicting prognosis (AUC = 0.800, P < 0.001).The sensitivity and specificity of HMGB-1, WBC, PLT, and ALB used in combination for predicting outcome were better than those of single analyses (AUC = 0.892, P < 0.001).

View Article: PubMed Central - PubMed

Affiliation: Center of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, China.

ABSTRACT

Objective: To examine the predictive capacity of the high mobility group box protein-1 (HMGB-1) for disease severity and prognosis of hemorrhagic fever with renal syndrome (HFRS).

Methods: One hundred and five HFRS patients and 28 controls were studied. The concentrations of HMGB-1 in the blood were measured with a commercially available ELISA. The levels of white blood cells (WBC), platelets (PLT), hematocrit (HCT), albumin (ALB), blood urea nitrogen (BUN), serum creatinine (Scr), and uric acid (UA) were routinely tested in the same time frame.

Results: The levels of HMGB-1 increased with the severity of the disease (P < 0.001). HMGB-1 was positively correlated with WBC and BUN and negatively correlated with PLT, ALB, and UA (P < 0.001). HMGB-1 showed statistical significance for predicting prognosis (AUC = 0.800, P < 0.001). The sensitivity and specificity of HMGB-1, WBC, PLT, and ALB used in combination for predicting outcome were better than those of single analyses (AUC = 0.892, P < 0.001).

Conclusions: HMGB-1 can be considered a novel biomarker for severity and outcome in patients with HFRS. The use of HMGB-1, WBC, PLT, and ALB in combination to predict the outcome in patients with HFRS exhibited an acceptable level of diagnostic capability.

No MeSH data available.


Related in: MedlinePlus

Use of HMGB-1, WBC, PLT, and ALB in combination to predict prognosis in patients with HFRS by ROC analysis. ROC, receiver operating characteristic; HMGB-1, high mobility group box protein-1; WBC, white blood cells; PLT, platelets; ALB, albumin.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4402477&req=5

fig3: Use of HMGB-1, WBC, PLT, and ALB in combination to predict prognosis in patients with HFRS by ROC analysis. ROC, receiver operating characteristic; HMGB-1, high mobility group box protein-1; WBC, white blood cells; PLT, platelets; ALB, albumin.

Mentions: ROC analysis revealed that HMGB-1 showed statistical significance for predicting prognosis with the area under the curve (AUC) equal to 0.800 (95% CI: 0.645–0.955, P < 0.001). The sensitivity and specificity of the HMGB-1, WBC, PLT, and ALB in combination for predicting outcome were better than with individual analysis (AUC = 0.892, P < 0.001) (Table 5, Figure 3).


HMGB-1 as a novel predictor of disease severity and prognosis in patients with hemorrhagic fever with renal syndrome.

Du H, Li J, Yu H, Lian J, Zhang Y, Zhang Y, Bai X, Wang P - Mediators Inflamm. (2015)

Use of HMGB-1, WBC, PLT, and ALB in combination to predict prognosis in patients with HFRS by ROC analysis. ROC, receiver operating characteristic; HMGB-1, high mobility group box protein-1; WBC, white blood cells; PLT, platelets; ALB, albumin.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4402477&req=5

fig3: Use of HMGB-1, WBC, PLT, and ALB in combination to predict prognosis in patients with HFRS by ROC analysis. ROC, receiver operating characteristic; HMGB-1, high mobility group box protein-1; WBC, white blood cells; PLT, platelets; ALB, albumin.
Mentions: ROC analysis revealed that HMGB-1 showed statistical significance for predicting prognosis with the area under the curve (AUC) equal to 0.800 (95% CI: 0.645–0.955, P < 0.001). The sensitivity and specificity of the HMGB-1, WBC, PLT, and ALB in combination for predicting outcome were better than with individual analysis (AUC = 0.892, P < 0.001) (Table 5, Figure 3).

Bottom Line: HMGB-1 was positively correlated with WBC and BUN and negatively correlated with PLT, ALB, and UA (P < 0.001).HMGB-1 showed statistical significance for predicting prognosis (AUC = 0.800, P < 0.001).The sensitivity and specificity of HMGB-1, WBC, PLT, and ALB used in combination for predicting outcome were better than those of single analyses (AUC = 0.892, P < 0.001).

View Article: PubMed Central - PubMed

Affiliation: Center of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, China.

ABSTRACT

Objective: To examine the predictive capacity of the high mobility group box protein-1 (HMGB-1) for disease severity and prognosis of hemorrhagic fever with renal syndrome (HFRS).

Methods: One hundred and five HFRS patients and 28 controls were studied. The concentrations of HMGB-1 in the blood were measured with a commercially available ELISA. The levels of white blood cells (WBC), platelets (PLT), hematocrit (HCT), albumin (ALB), blood urea nitrogen (BUN), serum creatinine (Scr), and uric acid (UA) were routinely tested in the same time frame.

Results: The levels of HMGB-1 increased with the severity of the disease (P < 0.001). HMGB-1 was positively correlated with WBC and BUN and negatively correlated with PLT, ALB, and UA (P < 0.001). HMGB-1 showed statistical significance for predicting prognosis (AUC = 0.800, P < 0.001). The sensitivity and specificity of HMGB-1, WBC, PLT, and ALB used in combination for predicting outcome were better than those of single analyses (AUC = 0.892, P < 0.001).

Conclusions: HMGB-1 can be considered a novel biomarker for severity and outcome in patients with HFRS. The use of HMGB-1, WBC, PLT, and ALB in combination to predict the outcome in patients with HFRS exhibited an acceptable level of diagnostic capability.

No MeSH data available.


Related in: MedlinePlus